Top Story

Self-administered latent TB therapy noninferior to direct observation

November 6, 2017

Read the Perspective from Karen Jacobson, MD, MPH

Patients in the United States who self-administered once-weekly isoniazid and rifapentine to treat latent tuberculosis infection had a high rate of treatment completion, demonstrating noninferiority to direct observation, according to Phase 4 study data.

“Cost-effectiveness modeling found that self-administered, once-weekly [isoniazid] and rifapentine had an advantage over other regimens if adherence remained high and toxicity did not increase,” Robert Belknap, MD, from Denver Health and Hospital Authority and the University of Colorado Health Sciences Center, and colleagues wrote in Annals of Internal Medicine. “However, adherence to the once-weekly regimen in the [self-administered therapy] groups was unknown, and the frequency and severity of adverse events in patients monitored at monthly visits rather than weekly during [directly observed therapy] had not been evaluated.”


WHO: Ending TB will take greater political commitment

October 30, 2017
Health experts warned that progress to end tuberculosis has stalled and that greater political commitment is needed to address the burden of the world’s No. 1…
In the Journals

Only 41% of TB cases in rural China correctly managed

October 24, 2017
Only 41% of tuberculosis cases in rural China — an area with a significant burden caused by the disease — are correctly managed in village clinics, township
In the Journals

Researchers identify patients not likely to complete TB treatment

August 4, 2017
Marital status, substance use and extent of medical history are among the factors that could determine which patients are most likely to finish latent tuberculosis…
More Headlines »
CME Article

Origins of Outcome Disparities in Pediatric Respiratory Disease

Pediatric Annals, December 2010, Volume 39 Issue 12
Respiratory diseases account for a significant portion of morbidity and mortality in pediatric medicine, but this…
More »
Meeting News Coverage

VIDEO: Mel Spigelman, MD, discusses TB drug pipeline

June 19, 2016
More »